Carelon’s AI-Enabled Whole Health Clinical Engagement assists by increasing care quality through predicting risks for depression and instigating effective, comprehensive interventions. The resulting transformative greatly benefits patient outcomes, reducing medical and behavioral complexities and improving the patient experience.
“By augmenting assessment practices, Carelon achieves a remarkable improvement in positive predictive value for depression risk identification, from 30% to over 90%, leading to more comprehensive and effective interventions.” – Judges’ comment.
It was noted that 20% of those above 65 have clinical depression, but identification through healthcare claims data is far from thorough. In trying to address the issue, Carelon faced barriers in depression identification due to the intensiveness of established clinical screening surveys, but perseverance paid off. Carelon augmented assessment practices, improving positive predictive value for depression risk among patients scheduled for surgery from 30% to over 90% through their clinical questionnaire-centric AI model.
As more data gets fed into the system, Carleon’s AI continuously learns and refines its precision and risk identification capabilities. This will enhance care quality, reduce risk of future health complications, and improve user experience indefinitely. With a 90% precision rate – and a timeline of continuous improvement – Carleon has developed an incredible tool for healthcare.
“Carelon’s integration of AI technology represents a groundbreaking innovation in healthcare, effectively addressing the social and emotional needs of at-risk patients undergoing physical health procedures. The use of a patent-pending AI algorithm demonstrates a high level of technological sophistication and ingenuity, enabling Carelon to engage patients holistically and predict risks for depression with unprecedented precision.” – Judges’ comment.
By adopting this system-integrated AI process, Carelon has achieved a higher engagement rate, with 33% of targeted outreach patients already engaged with the program. Furthermore, 20% of those engaged have had their social and emotional needs addressed, resulting in a reduction of medical and behavioral complexities. This model’s ability to cater to the healthcare needs of up to 600,000 members annually signals its considerable potential for growth.
It was shown that Carelon’s AI integration has successfully transformed the organization’s approach to healthcare. The tool has allowed for the delivery of versatile benefits – improving patient engagement rates and care quality to reducing future complications and significantly boosting prediction and detection abilities – enhancing the overall patient experience.
“Carelon’s AI-enabled whole health clinical engagement model exhibits considerable scalability and potential for growth, with the ability to cater to the healthcare needs of up to 600,000 members annually. The model’s continuous learning capabilities ensure ongoing refinement and improvement, enhancing its precision and risk identification capabilities over time.” – Judges’ comment.
